RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Zai Lab of Shanghai announced that the China National Medical Products Administration (NMPA) accepted its NDA for Zejula (niraparib), a novel Category 1 PARP1/2 drug — the first Zai NDA submission accepted in China. The candidate is indicated for maintenance treatment of patients with recurrent ovarian and fallopian tube cancer who are in a complete or partial response to platinum-based chemotherapy. According to Zai, Zejula is a potent, highly selective PARP1/2 inhibitor that does not require prior testing for BRCA mutation.
Source: China Biotoday
